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The influenza virus imposes a heavy burden for society in terms of health and economy. Influenza is an elusive 
enveloped virus due to antigenic shift and drift of two surface proteins: neuraminidase (NA) and hemagglutinin 
(HA). As a result, new strains emerge every year which require seasonal vaccination for protection. 
Furthermore, large vaccine quantities are urgently needed in case of pandemics. Theoretically, vaccines against 
a new strain can be manufactured in as little as three weeks with certain platforms and technologies. However, 
vaccine quantification and release are still relying on the use of the Single Radial Immunodiffusion (SRID) assay 
using a strain-specific antibody to calculate HA concentration. This is a major limitation because it can take up to 
three months to generate the reagents necessary to run the SRID assay, including the strain-specific antibody. 
Hence, one of the major hurdles in the process of influenza vaccine production is the quantification of HA which 
is critical to establish proper dosing.  
 
To circumvent the need for strain-specific antibodies, we have produced two monoclonal antibodies (F211-
11H12-3 and F211-10A9-2) against a highly conserved peptide sequence found within the HA molecule (1). 
Multiple strains belonging to 13 different influenza A subtypes, as well as 6 strains belonging to B lineages were 
detected by Western blot and dot blot. Overall, mAb F211-11H12-3 recognizes preferentially influenza A 
subtype 1, while the mAb F211-10A9-2 has a higher affinity for influenza A subtype 2. Therefore, all strains 
tested could be detected when both mAb are combined and used as a cocktail. Next, we performed quantitative 
dot blots by generating a standard curve ranging from 160ng/ml to 20µg/ml HA. This method is simple, easy to 
implement and highly reproducible. In-process samples as well as purified material can be quantified by dot blot 
after denaturation with urea. Even though the SRID is the only assay approved by regulatory agencies, 
quantitative dot blots can be used during manufacturing to optimize and monitor the production process. Finally, 
ELISA is widely used for quantification and preliminary data demonstrates that samples can be quantified with 
the pan-HA mAbs. 
 
In conclusion, a pan-HA antibody cocktail was generated against a highly conserved peptide sequence of 
influenza. Viruses produced in eggs and mammalian cells from 40 different strains were detected by Western 
blot. Reproducible quantification was achieved by dot blot using the two mAbs and an appropriate calibrating 
standard. The combination of pan-HA antibodies with an immunoassay such as the dot blot assay could 
accelerate process development and help establish new generation quantification methods for influenza. As the 
field is looking for flexible and versatile solutions to shift away from the SRID assay and strain-specific 
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